Sorrento And Mabpharm Get ‘Biobetter’ Infliximab Approval In China
Plans To File Biosimilar With Improved Safety Profile In US And Europe This Year
Executive Summary
Sorrento and Mabpharm have revealed plans to take their infliximab “biobetter” global, after China’s NMPA approved the product, which has an improved safety profile compared to Remicade.